Table of Content



Chapter 1 Methodology
1.1 Market segmentation
1.1.1 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-wise market estimation using the bottom-up approach
1.7 U.S. Market: CAGR Calculation
1.8 Research Assumptions
1.9 List of Secondary Sources
1.10 List of Primary Sources
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.12 List of Abbreviations
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Industry Outlook
3.1 Market Segmentation
3.2 Penetration & Growth Prospect Mapping
3.3 Regulatory and Reimbursement Framework
3.4 Market Variable Analysis
3.4.1 Market driver analysis
3.4.1.1 Increase in the number of patients undergoing Hormone Replacement Therapy
3.4.1.2 Rising prevalence of hormonal disorders
3.4.1.3 Technological developments in drug delivery systems
3.4.2 Market restraint analysis
3.4.2.1 High cost of treatment
3.4.2.2 Risk of side effects
3.5 Industry Analysis Tools
3.5.1 PESTEL Analysis
3.5.2 Porter’s five forces analysis
3.6 Major Deals and Strategic Alliances Analysis
3.6.1 New Product Launch
3.6.2 Mergers and Acquisitions
3.6.3 Promotional Agreements & Joint Ventures
3.6.4 Conferences and Campaigns
3.7 Pipeline Analysis
Chapter 4 U.S. Hormone Replacement Therapy Market: Product Segment Analysis
4.1 U.S. HRT Market: Product Movement Analysis
4.2 Estrogen & Progesterone Replacement Therapy
4.2.1 Estrogen & Progesterone replacement therapy market, 2016 - 2027 (USD Million)
4.3 Human Growth Hormone (HGH) Replacement Therapy
4.3.1 HGH replacement therapy market, 2016 - 2027 (USD Million)
4.4 Thyroid Hormone Replacement Therapy
4.4.1 Thyroid hormone replacement therapy market, 2016 - 2027 (USD Million)
4.5 Testosterone Replacement Therapy
4.5.1 Testosterone replacement therapy market, 2016 - 2027 (USD Million)
4.6 Parathyroid Hormone
4.6.1 Parathyroid Hormone market, 2016 - 2027 (USD Million)
Chapter 5 U.S. Hormone Replacement Therapy: Route of Administration Segment Analysis
5.1 U.S. HRT Market: Route of Administration Movement Analysis
5.2 Oral
5.2.1 Oral market, 2016 - 2027 (USD Million)
5.3 Parenteral
5.3.1 Parenteral market, 2016 - 2027 (USD Million)
5.4 Transdermal
5.4.1 Transdermal market, 2016 - 2027 (USD Million)
5.5 Others
5.5.1 Others market, 2016 - 2027 (USD Million)
Chapter 6 U.S. Hormone Replacement Therapy Market: Disease Type Segment Analysis
6.1 U.S. HRT Market: Disease Type Movement Analysis
6.2 Menopause
6.2.1 Menopause market, 2016 - 2027 (USD Million)
6.3 Hypothyroidism
6.3.1 Hypothyroidism market, 2016 - 2027 (USD Million)
6.4 Male Hypogonadism
6.4.1 Male Hypogonadism market, 2016 - 2027 (USD Million)
6.5 Growth Hormone Deficiency
6.5.1 Growth Hormone Deficiency market, 2016 - 2027 (USD Million)
6.6 Hypoparathyroidism
6.6.1 Hypoparathyroidism, 2016 - 2027 (USD Million)
Chapter 7 Hormone Replacement Therapy Market - Competitive Analysis
7.1 Company Categorization
7.1.1 Market Differentiators
7.1.2 Innovators
7.1.3 Market Leaders
7.2 Vendor Landscape
7.2.1 List of key distributors and channel partners
7.2.2 Key customers
7.3 Heat map analysis
7.4 Public Companies
7.4.1 Key company analysis, 2019
7.4.2 Company market position analysis
7.5 Company Profiles
7.5.1 Bayer AG
7.5.1.1 Company Overview
7.5.1.2 Financial Performance
7.5.1.3 Product Benchmarking
7.5.1.4 Strategic Initiatives
7.5.2 Pfizer, Inc.
7.5.2.1 Company Overview
7.5.2.2 Financial Performance
7.5.2.3 Product Benchmarking
7.5.2.4 Strategic Initiatives
7.5.3 Merck & Co., Inc.
7.5.3.1 Company Overview
7.5.3.2 Financial Performance
7.5.3.3 Product Benchmarking
7.5.3.4 Strategic Initiatives
7.5.4 Abbott
7.5.4.1 Company Overview
7.5.4.2 Financial Performance
7.5.4.3 Product Benchmarking
7.5.4.4 Strategic Initiatives
7.5.5 Mylan N.V.
7.5.5.1 Company Overview
7.5.5.2 Financial Performance
7.5.5.3 Product Benchmarking
7.5.5.4 Strategic Initiatives
7.5.6 Novo Nordisk A/S
7.5.6.1 Company Overview
7.5.6.2 Financial Performance
7.5.6.3 Product Pipeline
7.5.6.4 Strategic Initiatives
7.5.7 Eli Lilly and Company
7.5.7.1 Company Overview
7.5.7.2 Financial Performance
7.5.7.3 Product Benchmarking
7.5.7.4 Strategic Initiatives
7.5.8 F. Hoffmann-La Roche Ltd. (Genentech)
7.5.8.1 Company Overview
7.5.8.2 Financial Performance
7.5.8.3 Product Benchmarking
7.5.9 Noven Pharmaceuticals, Inc. (Hisamitsu Pharmaceutical Co., Inc.)
7.5.9.1 Company Overview
7.5.9.2 Financial Performance
7.5.9.3 Product Benchmarking
7.5.9.4 Strategic Initiatives
7.5.10 ASCEND Therapeutics US, LLC. (Besins Healthcare)
7.5.10.1 Company Overview
7.5.10.2 Product Benchmarking
7.5.10.3 Strategic Initiatives
7.5.11 AbbVie Inc.
7.5.11.1 Company Overview
7.5.11.2 Financial Performance
7.5.11.3 Product Benchmarking
7.5.11.4 Strategic Initiatives



List of Tables



TABLE 1 List of secondary sources
TABLE 2 List of Abbreviation
TABLE 3 Regulatory framework
TABLE 4 Eligibility table for menopause treatment services
TABLE 5 Eligibility table for hormone replacement therapy
TABLE 6 Leading market players are anticipated to witness the highest growth
TABLE 7 List of key distributors and Compounding Pharmacies
TABLE 8 Key Company Analysis
TABLE 9 U.S. Hormone Replacement Therapy Market, By product, 2016 - 2027 (USD Million)
TABLE 10 U.S. Hormone Replacement Therapy Market, By route of administration, 2016 - 2027 (USD Million)
TABLE 11 U.S. Hormone Replacement Therapy Market, By disease type, 2016 - 2027 (USD Million)